MX2009006308A - Derivados de benzoquinazol. - Google Patents

Derivados de benzoquinazol.

Info

Publication number
MX2009006308A
MX2009006308A MX2009006308A MX2009006308A MX2009006308A MX 2009006308 A MX2009006308 A MX 2009006308A MX 2009006308 A MX2009006308 A MX 2009006308A MX 2009006308 A MX2009006308 A MX 2009006308A MX 2009006308 A MX2009006308 A MX 2009006308A
Authority
MX
Mexico
Prior art keywords
halo
cyano
alkenyl
alkoxy
amino
Prior art date
Application number
MX2009006308A
Other languages
English (en)
Inventor
Leo Widler
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39523605&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009006308(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2009006308A publication Critical patent/MX2009006308A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un compuesto de la fórmula (I) o una sal farmacéuticamente aceptable o éster de pro-fármaco del mismo: (ver fórmula I) en donde -R representa un grupo de dos anillos fusionados -A-B; en donde A es hetero-arilo o arilo opcionalmente sustituido; y B es un anillo de 4, 5, 6, ó 7 miembros saturado o insaturado que contiene opcionalmente uno o más heteroátomos seleccionados a partir de O, N y S; siendo los sustituyentes opcionales sobre R uno o más grupos independientemente seleccionados a partir de oxo, ciano, halógeno o alquilo de 1 a 6 átomos de carbono, alquenilo de 2 a 6 átomos de carbono, alcoxilo de 1 a 6 átomos de carbono, y amino adicionalmente sustituidos opcionalmente; siendo los sustituyentes opcionales adicionales seleccionados a partir de ciano, halógeno, alquilo de 1 a 6 átomos de carbono, alquenilo de 1 a 6 átomos de carbono, alcoxilo de 1 a 6 átomos de carbono, y amino; para promover la liberación de la hormona paratiroides; para prevenir o tratar condiciones óseas que estén asociadas con un mayor consumo o resorción de calcio, o en donde sea deseable el estímulo de la formación ósea y la fijación de calcio en el hueso.
MX2009006308A 2007-01-22 2008-01-21 Derivados de benzoquinazol. MX2009006308A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07100937A EP1956019A1 (en) 2007-01-22 2007-01-22 Benzoquinazoline derivatives
PCT/EP2008/000415 WO2008089933A2 (en) 2007-01-22 2008-01-21 Benzoquinazole derivatives

Publications (1)

Publication Number Publication Date
MX2009006308A true MX2009006308A (es) 2009-08-13

Family

ID=39523605

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009006308A MX2009006308A (es) 2007-01-22 2008-01-21 Derivados de benzoquinazol.

Country Status (15)

Country Link
US (1) US20100099670A1 (es)
EP (2) EP1956019A1 (es)
JP (1) JP2010516647A (es)
KR (1) KR20090101275A (es)
CN (1) CN101578280A (es)
AR (1) AR064964A1 (es)
AU (1) AU2008209103A1 (es)
BR (1) BRPI0806888A2 (es)
CA (1) CA2674921A1 (es)
CL (1) CL2008000169A1 (es)
EA (1) EA200900941A1 (es)
MX (1) MX2009006308A (es)
PE (1) PE20081702A1 (es)
TW (1) TW200836742A (es)
WO (1) WO2008089933A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102056897B (zh) 2008-06-05 2014-05-07 旭化成制药株式会社 磺酰胺化合物及其用途
JP5654246B2 (ja) * 2010-03-03 2015-01-14 一般社団法人ファルマバレープロジェクト支援機構 キナゾリン化合物を有効成分とする医薬組成物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0230015D0 (en) * 2002-12-23 2003-01-29 Novartis Ag Organic compounds
GB0516723D0 (en) * 2005-08-15 2005-09-21 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
BRPI0806888A2 (pt) 2014-04-29
EP1956019A1 (en) 2008-08-13
PE20081702A1 (es) 2008-12-31
JP2010516647A (ja) 2010-05-20
CA2674921A1 (en) 2008-07-31
CN101578280A (zh) 2009-11-11
CL2008000169A1 (es) 2008-08-08
WO2008089933A3 (en) 2008-09-12
AR064964A1 (es) 2009-05-06
EP2106400A2 (en) 2009-10-07
TW200836742A (en) 2008-09-16
AU2008209103A1 (en) 2008-07-31
WO2008089933A2 (en) 2008-07-31
EA200900941A1 (ru) 2010-02-26
US20100099670A1 (en) 2010-04-22
KR20090101275A (ko) 2009-09-24

Similar Documents

Publication Publication Date Title
MX2009005449A (es) Compuesto heteromonociclico y uso del mismo.
RS20060699A (en) Isoxazolines for controlling inverterbrate pests
MX2010002258A (es) Compuestos terapeuticos de isoxazol.
MXPA05010712A (es) Derivados de quinolin-2-ona para el tratamiento de enfermedades de las vias respiratorias.
AR040278A1 (es) Ligandos del receptor de glucocorticoides para el tratamiento de trastornos metabolicos
AP1822A (en) Substituted pyridinones as modulators of P38 MAP kinase.
MY152921A (en) Aryl-quinazoline/aryl-2-amino-phenyl methanone derivatives
WO2005070884A3 (en) Heterocyclic compounds useful as growth hormone secretagogues
PE20061084A1 (es) Compuestos derivados de 2-ciano-3-(halo)alcoxi-bencenosulfonamida
PE20060648A1 (es) Procesos para la preparacion de 2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolinas sustituidas
TW200616979A (en) Non-nucleoside reverse transcriptase inhibitors
MX2022015551A (es) Metodos de sintesis para la preparacion de 4-(2-cloro-4-metoxi-5-m etilfenil)-n-[(1s)-2-ciclopropil-1-(3-fluoro-4-metilfenil)etil]-5 -metil-n-prop-2-inil-1,3-tiazol-2-amina.
NO20080391L (no) Pyrazolbaserte LXR modulatorer
BR0317435A (pt) Derivados de pirimidina para o tratamento do crescimento celular anormal
PE20021005A1 (es) Quinazolinas como inhibidores de mmp-13
NZ590334A (en) ICOTINIB HYDROCHLORIDE (4-[(3-ethynylphenyl)amino]-6,7-benzo-12-crownquinazoline hydrochloride), SYNTHESIS, CRYSTALLOGRAPHIC FORM, MEDICAL COMBINATION, AND USES THEREOF
MX2015008971A (es) Derivados de pirimidina pirido- o pirrolo-fusionados como inhibidores de autotaxina para tratar dolor.
MX2009003739A (es) Derivados de hidrobenzamida como inhibidores de hsp90.
PE20090601A1 (es) Derivados de piridin-il-oxi-piridinas como inhibidores de alk5
TW200700398A (en) Substituted n-sulfonylaminophenylethyl-2-phenoxyacetamide compounds
MX2009010083A (es) Compuestos biarilo y biheteroarilo de utilidad en el tratamiento de trastornos de hierro.
PE20060355A1 (es) TIENO[3,2-b]PIRIDIN-6-CARBONITRILOS COMO INHIBIDORES DE LA QUINASA PROTEICA
BRPI0408353A (pt) composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto
MX2010000658A (es) Derivados de pirimidina 934.
MY136824A (en) Substituted benzoxazinones and uses thereof

Legal Events

Date Code Title Description
FA Abandonment or withdrawal